NASDAQ:EPZM - Epizyme Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.33
  • Forecasted Upside: 140.55 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.17 (-2.44%)

This chart shows the closing price for EPZM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Epizyme Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EPZM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EPZM

Analyst Price Target is $16.33
▲ +140.55% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Epizyme in the last 3 months. The average price target is $16.33, with a high forecast of $27.00 and a low forecast of $10.00. The average price target represents a 140.55% upside from the last price of $6.79.

This chart shows the closing price for EPZM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Epizyme. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2021Morgan StanleyLower Price TargetEqual Weight$11.00 ➝ $10.00High
5/7/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$12.00 ➝ $16.00High
4/19/2021Morgan StanleyLower Price TargetEqual Weight$14.00 ➝ $11.00Medium
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$13.00High
3/3/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$14.00N/A
2/25/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$14.00High
2/24/2021CitigroupLower Price Target$35.00 ➝ $27.00Medium
2/23/2021WedbushReiterated RatingOutperformHigh
2/5/2021SVB LeerinkReiterated RatingMarket PerformLow
12/21/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$18.00 ➝ $14.00Low
11/9/2020Morgan StanleyLower Price TargetOverweight$29.00 ➝ $27.00High
11/9/2020BarclaysLower Price TargetOverweight$33.00 ➝ $18.00High
8/5/2020Morgan StanleyLower Price TargetOverweight$31.00 ➝ $29.00Medium
6/19/2020SVB LeerinkLower Price TargetMarket Perform$18.00 ➝ $16.00High
6/19/2020Morgan StanleyBoost Price TargetOverweight$28.00 ➝ $31.00High
5/5/2020OppenheimerReiterated RatingHold$16.00 ➝ $17.00High
4/1/2020OppenheimerDowngradeOutperform ➝ Market Perform$17.00 ➝ $16.00High
3/4/2020BarclaysInitiated CoverageOverweight$33.00High
2/25/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $36.00Low
1/24/2020Morgan StanleyBoost Price TargetOverweight$26.00 ➝ $28.00High
1/24/2020CowenBoost Price TargetOutperform$18.00 ➝ $36.00High
1/24/2020WedbushBoost Price TargetOutperform$24.00 ➝ $30.00High
1/23/2020CitigroupBoost Price TargetBuy$25.00 ➝ $35.00Medium
12/19/2019WedbushReiterated RatingOutperform$24.00High
12/5/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$12.00 ➝ $22.00High
10/31/2019HC WainwrightReiterated RatingBuyHigh
10/31/2019CowenReiterated RatingBuy$18.00Low
6/24/2019HC WainwrightSet Price TargetBuy$25.00Medium
6/13/2019HC WainwrightSet Price TargetBuy$25.00Medium
6/12/2019WedbushReiterated RatingOutperform$21.00Low
5/31/2019HC WainwrightSet Price TargetBuy$25.00Low
5/30/2019CitigroupReiterated RatingBuyHigh
2/27/2019Roth CapitalReiterated RatingBuyLow
2/27/2019OppenheimerLower Price TargetOutperform$27.00 ➝ $18.00Low
2/26/2019CowenReiterated RatingBuy$18.00Medium
1/7/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$12.00High
1/4/2019OppenheimerSet Price TargetBuy$27.00High
11/15/2018OppenheimerSet Price TargetBuy$27.00Low
11/5/2018Morgan StanleyLower Price TargetEqual Weight ➝ Hold$12.00 ➝ $11.00Low
11/5/2018WedbushReiterated RatingOutperform$21.00Medium
11/2/2018OppenheimerSet Price TargetBuy$27.00Medium
10/22/2018Roth CapitalSet Price TargetBuy$26.00 ➝ $18.00Low
9/25/2018SunTrust BanksBoost Price TargetBuy$25.00Medium
9/24/2018SVB LeerinkInitiated CoverageMarket Perform$11.00Medium
9/24/2018CowenReiterated RatingBuyHigh
9/7/2018Morgan StanleyInitiated CoverageEqual ➝ Equal WeightLow
9/7/2018Morgan StanleySet Price TargetEqual Weight ➝ Hold$12.00Medium
7/3/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$24.00High
6/27/2018HC WainwrightReiterated RatingBuy$25.00High
5/21/2018HC WainwrightReiterated RatingBuy$25.00Low
5/18/2018WedbushBoost Price Target$20.00 ➝ $25.00Low
4/24/2018Roth CapitalSet Price TargetBuy$24.00Medium
4/24/2018SVB LeerinkSet Price TargetBuy$24.00High
4/24/2018WedbushLower Price TargetHold ➝ Outperform$24.00 ➝ $20.00High
4/24/2018SunTrust BanksLower Price TargetBuy ➝ Hold$20.00High
3/14/2018WedbushReiterated RatingOutperform$26.00 ➝ $25.00High
3/14/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$22.00 ➝ $24.00High
3/14/2018SunTrust BanksReiterated RatingBuy$27.00High
2/1/2018Roth CapitalInitiated CoverageBuy$24.00Medium
1/24/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy$25.00Low
1/10/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$20.00High
12/12/2017OppenheimerSet Price TargetBuy$26.00Medium
11/2/2017HC WainwrightReiterated RatingBuy$25.00N/A
11/2/2017SVB LeerinkReiterated RatingOutperform$28.00 ➝ $22.00N/A
11/2/2017Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$20.00 ➝ $16.00N/A
9/20/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$23.00Medium
9/19/2017OppenheimerReiterated RatingBuy$26.00Low
9/15/2017Royal Bank of CanadaReiterated RatingBuy$20.00Low
8/9/2017SVB LeerinkReiterated RatingOutperform$31.00 ➝ $28.00Medium
8/7/2017HC WainwrightReiterated RatingBuyMedium
8/5/2017Royal Bank of CanadaSet Price TargetBuy$20.00High
6/16/2017SVB LeerinkReiterated RatingOutperform$31.00High
6/16/2017CitigroupBoost Price TargetBuy$20.00 ➝ $22.00Low
6/14/2017OppenheimerSet Price TargetBuy$26.00High
6/12/2017Royal Bank of CanadaSet Price TargetBuy$20.00Low
6/7/2017CowenReiterated RatingBuyHigh
6/7/2017HC WainwrightReiterated RatingBuy$25.00Medium
6/5/2017OppenheimerSet Price TargetBuy$26.00Medium
5/19/2017HC WainwrightReiterated RatingBuyLow
5/18/2017WedbushReiterated RatingOutperform$24.00High
5/10/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$19.00 ➝ $20.00Low
4/13/2017CIBCReiterated RatingOutperform ➝ OutperformLow
4/13/2017OppenheimerInitiated CoverageOutperform$26.00Low
3/11/2017Royal Bank of CanadaReiterated RatingOutperform$26.00 ➝ $19.00N/A
11/28/2016WedbushReiterated RatingOutperform$22.00N/A
11/6/2016JMP SecuritiesReiterated RatingBuyN/A
11/6/2016HC WainwrightReiterated RatingBuyN/A
11/4/2016WedbushReiterated RatingOutperform$22.00N/A
10/7/2016SVB LeerinkReiterated RatingOutperformN/A
8/9/2016HC WainwrightReiterated RatingBuyN/A
(Data available from 7/26/2016 forward)
Epizyme logo
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.79
Low: $6.73
High: $7.02

50 Day Range

MA: $8.28
Low: $6.96
High: $9.71

52 Week Range

Now: $6.79
Low: $6.70
High: $14.93


17,036 shs

Average Volume

1,066,129 shs

Market Capitalization

$692.42 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Epizyme?

The following Wall Street research analysts have issued reports on Epizyme in the last year: Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Jefferies Financial Group Inc., Morgan Stanley, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for EPZM.

What is the current price target for Epizyme?

6 Wall Street analysts have set twelve-month price targets for Epizyme in the last year. Their average twelve-month price target is $16.33, suggesting a possible upside of 134.7%. Citigroup Inc. has the highest price target set, predicting EPZM will reach $27.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $10.00 for Epizyme in the next year.
View the latest price targets for EPZM.

What is the current consensus analyst rating for Epizyme?

Epizyme currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EPZM will outperform the market and that investors should add to their positions of Epizyme.
View the latest ratings for EPZM.

What other companies compete with Epizyme?

How do I contact Epizyme's investor relations team?

Epizyme's physical mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company's listed phone number is 617-229-5872 and its investor relations email address is [email protected] The official website for Epizyme is